ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW

American Journal of Translational Research

Volumn 4, Issue 3, 2012, Pages 333-346

  Zhang, Yin ^a   Hong, Hao ^b   Severin, Gregory W ^a   Engle, Jonathan W ^a   Yang, Yunan ^b   Goel, Shreya ^c   Nathanson, Alex J ^a   Liu, Glenn ^a,d   Nickles, Robert J ^a   Leigh, Bryan R ^e   Barnhart, Todd E ^a   Cai, Weibo ^a,b,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

^d UNIVERSITY OF WISCONSIN   (United States)

^e TRACON Pharmaceuticals Inc   (United States)

Author keywords

CD105 endoglin; Near infrared fluorescence (NIRF); Positron emission tomography (PET); TRC105; Tumor angiogenesis

Indexed keywords

4 ISOTHIOCYANATOBENZYL DESFERRIOXAMINE CETUXIMAB 800CW ZR 89 CONJUGATE; 4 ISOTHIOCYANATOBENZYL DESFERRIOXAMINE TRC105 800CW ZR 89 CONJUGATE; CETUXIMAB; ENDOGLIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRC105; TRACER; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER MODEL; CONJUGATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TUMOR LEVEL; EX VIVO STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VIVO STUDY; MEDICAL DEVICE; MOUSE; NEAR INFRARED FLUORESCENCE IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOACTIVITY; SOLID TUMOR;

EID: 84864964195     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Cai W and Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008; 49 Suppl 2: 113S-128S.
3. Beer AJ and Schwaiger M. Imaging of integrin avb3 expression. Cancer Metastasis Rev 2008; 27: 631-644.
4. Cai W and Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci 2007; 12: 4267-4279.
5. Cai W, Niu G and Chen X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 2008; 14: 2943-2973.
6. Dijkgraaf I and Boerman OC. Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm 2009; 24: 637-647.
7. Cai W and Hong H. Peptoid and positron emission tomography: an appealing combination. Am J Nucl Med Mol Imaging 2011; 1: 76-79.
8. Hao G, Hajibeigi A, De León-Rodríguez LM, Öz OK and Sun X. Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression. Am J Nucl Med Mol Imaging 2011; 1: 65-75.
9. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ and Ellis LM. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-1937.
10. Fonsatti E, Nicolay HJ, Altomonte M, Covre A and Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010; 86: 12-19.
11. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H and Haruta Y. Endoglin-targeted cancer therapy. Curr Drug Deliv 2011; 8: 135-143.
12. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P and Taranger-Charpin C. Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGFR2, Tie-2/Tek and CD105 expression in breast cancer (n=905). Br J Cancer 2004; 90: 1216-1221.
13. Zhang D, Feng XY, Henning TD, Wen L, Lu WY, Pan H, Wu X and Zou LG. MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur J Radiol 2009; 70: 180-189.
14. Bredow S, Lewin M, Hofmann B, Marecos E and Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 2000; 36: 675-681.
15. Costello B, Li C, Duff S, Butterworth D, Khan A, Perkins M, Owens S, Al-Mowallad AF, O'Dwyer S and Kumar S. Perfusion of 99mTc-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer 2004; 109: 436-441.
16. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M and Maio M. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000; 6: 2037-2043.
17. Korpanty G, Carbon JG, Grayburn PA, Fleming JB and Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007; 13: 323-330.
18. Korpanty G, Grayburn PA, Shohet RV and Brekken RA. Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol 2005; 31: 1279-1283.
19. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, Leigh BR and Cai W. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 2011; 38: 1335-1343.
20. Zhang Y, Hong H and Cai W. PET tracers based on Zirconium-89. Curr Radiopharm 2011; 4: 131-139.
21. Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, Liu G, Leigh BR, Nickles RJ and Cai W. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging 2012; 39: 138-148.
22. Zhang Y, Hong H, Engle JW, Bean J, Yang Y, Leigh BR, Barnhart TE and Cai W. Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One 2011; 6: e28005.
23. Yang Y, Zhang Y, Hong H, Liu G, Leigh BR and Cai W. In vivo near-infrared fluorescence imaging of CD105 expression. Eur J Nucl Med Mol Imaging 2011; 38: 2066-2076.
24. Eary JF, Hawkins DS, Rodler ET and Conrad EUI. 18F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging 2011; 1: 47-53.
25. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE and Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S.
26. Iagaru A. 18F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. Am J Nucl Med Mol Imaging 2011; 1: 63-64.
27. Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P and Fanti S. The clinical use of PET with 11C-acetate. Am J Nucl Med Mol Imaging 2012; 2: 33-47.
28. Alauddin MM. Positron emission tomography (PET) imaging with 18F-based radiotracers. Am J Nucl Med Mol Imaging 2012; 2: 55-76.
29. Vach W, Høilund-Carlsen PF, Fischer BM, Gerke O and Weber W. How to study optimal timing of PET/CT for monitoring of cancer treatment. Am J Nucl Med Mol Imaging 2011; 1: 54-62.
30. van Dongen GA and Vosjan MJ. Immunopositron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm 2010; 25: 375-385.
31. Holland JP, Sheh Y and Lewis JS. Standardized methods for the production of high specificactivity zirconium-89. Nucl Med Biol 2009; 36: 729-739.
32. Wadas TJ, Wong EH, Weisman GR and Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010; 110: 2858-2902.
33. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schroder CP, Lub-de Hooge MN and de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87: 586-592.
34. Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE and van Dongen GA. p Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 2010; 37: 250-259.
35. James ML and Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 2012; 92: 897-965.
36. Cai W and Hong H. In a "nutshell": intrinsically radio-labeled quantum dots. Am J Nucl Med Mol Imaging 2012; 2: 136-140.
37. Thorek DLJ, Robertson R, Bacchus WA, Hahn J, Rothberg J, Beattie BJ and Grimm J. Cerenkov imaging-a new modality for molecular imaging. Am J Nucl Med Mol Imaging 2012; 2: 163-173.
38. Zeman MN and Scott PJH. Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging 2012; 2: 174-220.
39. Zhang Y and Cai W. Molecular imaging of insulin-like growth factor 1 receptor in cancer. Am J Nucl Med Mol Imaging 2012; 2: 248-259.
40. Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE and Cai W. Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging 2012; 2: 1-13.
41. Cai W, Hsu AR, Li ZB and Chen X. Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett 2007; 2: 265-281.
42. Mendelson DS, Gordon MS, Rosen LS, Hurwitz H, Wong MK, Adams BJ, Alvarez D, Seon BK, Theuer CP and Leigh BR. Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer. J Clin Oncol 2010; 28: 15s.
43. Wang H, Cai W, Chen K, Li ZB, Kashefi A, He L and Chen X. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 2007; 34: 2001-2010.
44. Takahashi N, Haba A, Matsuno F and Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001; 61: 7846-7854.
45. Cai W, Wu Y, Chen K, Cao Q, Tice DA and Chen X. In vitro and in vivo characterization of 64Culabeled AbegrinTM, a humanized monoclonal antibody against integrin avb3. Cancer Res 2006; 66: 9673-9681.
46. Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG and Chen X. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47: 2048-2056.
47. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M and Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999; 5: 371-382.
48. Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, Tice DA and Chen X. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 2007; 34: 2024-2036.
49. Meijs WE, Herscheid JDM, Haisma HJ and Pinedo HM. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Int J Radiat Appl Instrum, A, Appl Radiat Isot 1992; 43: 1443-1447.
50. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE and van Dongen GA. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyldesferrioxamine. Nat Protoc 2010; 5: 739-743.
51. Borjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, Lammertsma AA and van Dongen GA. Performance of immunopositron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006; 12: 2133-2140.
52. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT and Boerman OC. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med 2010; 51: 1565-1572.